Imugene Ltd - Several incremental positives in the past month

128 Views10 Jun 2026 10:00

Issuer-paid

SUMMARY

Imugene Ltd (ASX:IMU) is a clinical-stage immuno-oncology company that has transitioned from a wide-ranging pipeline into a highly-focused vehicle concentrating on CAR-T.
It is currently developing its platform azer-cel, an allogeneic ‘off-the-shelf’ CD19 CAR-T cell therapy for blood cancers.
Since our Initiation Report on 11 May 2026, IMU has issued several ASX announcements that we summarise in this report.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream